{"id":"alfuzosin-sl770499","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"2-5%","effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL1723","moleculeType":"Small molecule","molecularWeight":"425.92"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking alpha-1 adrenergic receptors, alfuzosin reduces the muscle tone in the prostate and bladder neck, allowing for easier urination. This is particularly beneficial for men with benign prostatic hyperplasia (BPH).","oneSentence":"Alfuzosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:41.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia (BPH)"}]},"trialDetails":[{"nctId":"NCT00576823","phase":"PHASE3","title":"Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Hydronephrosis, Neurogenic Bladder","enrollment":25},{"nctId":"NCT00549939","phase":"PHASE3","title":"Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Neurogenic Urinary Bladder","enrollment":172},{"nctId":"NCT00941343","phase":"NA","title":"Benign Prostatic Hyperplasia in Taiwan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Prostatic Diseases","enrollment":362},{"nctId":"NCT00629720","phase":"PHASE3","title":"Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-07","conditions":"Urinary Bladder Neurogenic","enrollment":29},{"nctId":"NCT00029822","phase":"PHASE3","title":"Clinical Trial in Males With BPH (Enlarged Prostate)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-05","conditions":"Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy","enrollment":1522}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"alfuzosin (SL770499)","genericName":"alfuzosin (SL770499)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alfuzosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow. Used for Benign prostatic hyperplasia (BPH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}